Literature DB >> 22206049

Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer.

Yanyuan Wu, Yayha Elshimali, Marianna Sarkissyan, Hezla Mohamed, Sheila Clayton, Jaydutt V Vadgama.   

Abstract

PURPOSE: To determine the prognostic value of FOXO1, GATA3 and Annexin-1 expression in breast cancer.
METHODS: Tissue microarray and individual paraffin tissue slides from 131 patients were used for the study. The association of FOXO1, GATA3 and Annexin-1 expression with clinicopathological features of breast cancer and disease outcome was examined in retrospective samples. Kaplan-Meier survival curves and Cox regression with multivariate analysis were used for assessing the relative risk (RR) and disease-free survival (DFS). The expression of FOXO1, GATA3 and Annexin-1 were determined by immunohistochemistry and the association among the three proteins was analyzed by Logistic regression analysis.
RESULTS: The nuclear expression of FOXO1 was observed in most of the normal breast tissues and 51.3% of the malignant breast tissues. GATA3 and Annexin-1 were expressed at 73% and 24.6% respectively in breast cancer tissues. The expression of FOXO1, GATA3 and Annexin-1 were all inversely correlated with lymph node-positive tumors. Both FOXO1 and Annexin-1 expression were also inversely associated with HER2-overexpressing tumors. FOXO1 expression was significantly associated with both GATA3 and Annexin-1 expression. In addition, Multivariate analyses confirm that only FOXO1 levels independently predict DFS.
CONCLUSION: FOXO1 expression in breast cancer is regulated by the PI3K/Akt pathway. The expression of FOXO1 is also associated with GATA3 and/or Annexin-1. Restoring or targeting FOXO1 to the cell nucleus in breast cancer tissues may improve response to therapy and disease outcome. Further clinical studies are warranted to test this hypothesis.

Entities:  

Keywords:  FOXO1; GATA3; annexin-1; breast cancer; survival

Year:  2011        PMID: 22206049      PMCID: PMC3236574     

Source DB:  PubMed          Journal:  Am J Cancer Res        ISSN: 2156-6976            Impact factor:   6.166


  45 in total

1.  Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.

Authors:  Michael F Press; Dennis J Slamon; Kerry J Flom; Jinha Park; Jian-Yuan Zhou; Leslie Bernstein
Journal:  J Clin Oncol       Date:  2002-07-15       Impact factor: 44.544

2.  Comprehensive characterization of annexin I alterations in esophageal squamous cell carcinoma.

Authors:  Nan Hu; Michael J Flaig; Hua Su; Jian-Zhong Shou; Mark J Roth; Wen-Jun Li; Chaoyu Wang; Alisa M Goldstein; Guang Li; Michael R Emmert-Buck; Philip R Taylor
Journal:  Clin Cancer Res       Date:  2004-09-15       Impact factor: 12.531

Review 3.  The emerging roles of forkhead box (Fox) proteins in cancer.

Authors:  Stephen S Myatt; Eric W-F Lam
Journal:  Nat Rev Cancer       Date:  2007-11       Impact factor: 60.716

4.  Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.

Authors:  Charles L Vogel; Melody A Cobleigh; Debu Tripathy; John C Gutheil; Lyndsay N Harris; Louis Fehrenbacher; Dennis J Slamon; Maureen Murphy; William F Novotny; Michael Burchmore; Steven Shak; Stanford J Stewart; Michael Press
Journal:  J Clin Oncol       Date:  2002-02-01       Impact factor: 44.544

5.  Androgens negatively regulate forkhead transcription factor FKHR (FOXO1) through a proteolytic mechanism in prostate cancer cells.

Authors:  Haojie Huang; David C Muddiman; Donald J Tindall
Journal:  J Biol Chem       Date:  2004-01-15       Impact factor: 5.157

6.  Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer.

Authors:  Lu Gan; Shuai Chen; Yuwei Wang; Akira Watahiki; Laura Bohrer; Zhen Sun; Yuzhuo Wang; Haojie Huang
Journal:  Cancer Res       Date:  2009-10-13       Impact factor: 12.701

7.  Role of FoxO1 activation in MDR1 expression in adriamycin-resistant breast cancer cells.

Authors:  Chang-Yeob Han; Kyoung-Bin Cho; Hong-Seok Choi; Hyo-Kyung Han; Keon-Wook Kang
Journal:  Carcinogenesis       Date:  2008-04-04       Impact factor: 4.944

8.  Annexin A1 down-regulation in head and neck cancer is associated with epithelial differentiation status.

Authors:  Juana Maria Garcia Pedrero; M Pilar Fernandez; Reginald O Morgan; Agustin Herrero Zapatero; Maria Victoria Gonzalez; Carlos Suarez Nieto; Juan Pablo Rodrigo
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

9.  Anastrozole versus tamoxifen as first-line therapy in postmenopausal patients with hormone-dependent advanced breast cancer: a prospective, randomized, phase III study.

Authors:  Alfredo Milla-Santos; Lidon Milla; Jordi Portella; Lidon Rallo; Maria Pons; Esther Rodes; Jose Casanovas; Margarita Puig-Gali
Journal:  Am J Clin Oncol       Date:  2003-06       Impact factor: 2.339

10.  Meta-analysis of human cancer microarrays reveals GATA3 is integral to the estrogen receptor alpha pathway.

Authors:  Brian J Wilson; Vincent Giguère
Journal:  Mol Cancer       Date:  2008-06-04       Impact factor: 27.401

View more
  20 in total

1.  Annexin 1 and its evolving role in systemic carcinogenesis besides its role in the pathogenesis of breast carcinomas.

Authors:  Shailendra Kapoor
Journal:  Am J Cancer Res       Date:  2012-06-28       Impact factor: 6.166

Review 2.  The HER2 Signaling Network in Breast Cancer--Like a Spider in its Web.

Authors:  A Dittrich; H Gautrey; D Browell; A Tyson-Capper
Journal:  J Mammary Gland Biol Neoplasia       Date:  2014-12-28       Impact factor: 2.673

3.  MicroRNA-9 promotes the proliferation, migration, and invasion of breast cancer cells via down-regulating FOXO1.

Authors:  D-Z Liu; B Chang; X-D Li; Q-H Zhang; Y-H Zou
Journal:  Clin Transl Oncol       Date:  2017-04-10       Impact factor: 3.405

4.  Analysis of FOXO1 mutations in diffuse large B-cell lymphoma.

Authors:  Diane L Trinh; David W Scott; Ryan D Morin; Maria Mendez-Lago; Jianghong An; Steven J M Jones; Andrew J Mungall; Yongjun Zhao; Jacqueline Schein; Christian Steidl; Joseph M Connors; Randy D Gascoyne; Marco A Marra
Journal:  Blood       Date:  2013-03-04       Impact factor: 22.113

5.  IGF-1 regulates Cyr61 induced breast cancer cell proliferation and invasion.

Authors:  Suren Sarkissyan; Marianna Sarkissyan; Yanyuan Wu; Jessica Cardenas; H Phillip Koeffler; Jaydutt V Vadgama
Journal:  PLoS One       Date:  2014-07-25       Impact factor: 3.240

6.  Slug contributes to cancer progression by direct regulation of ERα signaling pathway.

Authors:  Youqiang Li; Yanyuan Wu; Thomas C Abbatiello; Warren L Wu; Ju Ri Kim; Marianna Sarkissyan; Suren Sarkissyan; Seyung S Chung; Yahya Elshimali; Jaydutt V Vadgama
Journal:  Int J Oncol       Date:  2015-02-05       Impact factor: 5.650

7.  GATA3 Expression Is a Poor Prognostic Factor in Soft Tissue Sarcomas.

Authors:  Toshiaki Haraguchi; Hiroaki Miyoshi; Koji Hiraoka; Shintaro Yokoyama; Yukinao Ishibashi; Toshihiro Hashiguchi; Koutaro Matsuda; Tetsuya Hamada; Takahiro Okawa; Naoto Shiba; Koichi Ohshima
Journal:  PLoS One       Date:  2016-06-01       Impact factor: 3.240

8.  MicroRNA-552 Accelerates the Progression of Gastric Cancer by Targeting FOXO1 and Regulating PI3K/AKT Pathway.

Authors:  Yuguo Zhao; Jianwen Zhang; Wenbin Yang; Zhao Yang; Kaikai Zhou
Journal:  J Oncol       Date:  2021-05-04       Impact factor: 4.375

9.  STAT3 activation in HER2-overexpressing breast cancer promotes epithelial-mesenchymal transition and cancer stem cell traits.

Authors:  Seyung S Chung; Nolan Giehl; Yanyuan Wu; Jaydutt V Vadgama
Journal:  Int J Oncol       Date:  2013-11-29       Impact factor: 5.650

10.  Triple negative breast tumors in African-American and Hispanic/Latina women are high in CD44+, low in CD24+, and have loss of PTEN.

Authors:  Yanyuan Wu; Marianna Sarkissyan; Yahya Elshimali; Jaydutt V Vadgama
Journal:  PLoS One       Date:  2013-10-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.